Targeting Alternative Splicing as a Potential Therapy for Episodic Ataxia Type 2
Episodic ataxia type 2 (EA2) is an autosomal dominant neurological disorder characterized by paroxysmal attacks of ataxia, vertigo, and nausea that usually last hours to days. It is caused by loss-of-function mutations in <i>CACNA1A</i>, the gene encoding the pore-forming α<sub>1&l...
Main Authors: | Fanny Jaudon, Simona Baldassari, Ilaria Musante, Agnes Thalhammer, Federico Zara, Lorenzo A. Cingolani |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/8/9/332 |
Similar Items
-
Therapy of episodic ataxias: case report and review of the literature
by: Daniele Orsucci, et al.
Published: (2019-03-01) -
Episodic Vestibulocerebellar Ataxia Associated with a CACNA1G Missense Variant
by: José Gazulla, et al.
Published: (2021-06-01) -
Disrupted Calcium Signaling in Animal Models of Human Spinocerebellar Ataxia (SCA)
by: Francesca Prestori, et al.
Published: (2019-12-01) -
Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides
by: Zhenxun Wang, et al.
Published: (2012-01-01) -
HNRNPM controls circRNA biogenesis and splicing fidelity to sustain cancer cell fitness
by: Jessica SY Ho, et al.
Published: (2021-06-01)